Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer

Cytometry Part B - Clinical Cytometry

Volumn 76, Issue 2, 2009, Pages 107-117

  Goodale, David ^a   Phay, Carolina ^b   Brown, Wendy ^b   Gray Statchuk, Leslie ^b   Furlong, Patricia ^a,c,d   Lock, Michael ^a,c   Chin Yee, Ian ^a,b,c   Keeney, Michael ^b,c  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Breast cancer; CD146; CD163; CD64; Circulating endothelial cells; Flow cytometry; Monocyte activation

Indexed keywords

CD146 ANTIGEN; CD163 ANTIGEN; CD64 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; METASTASIS POTENTIAL; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; MONOCYTES; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 66249101667     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20449     Document Type: Article

References (62)

1. Canadian Cancer Statistics. Available at www.cancer.ca. Toronto: National Cancer Institute of Canada; Accessed: May 1, 2008.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572.
4. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-456.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930-942.
7. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: Opportunities for new therapeutic approaches. Nat Med 1997;3: 505-509.
8. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-849.
9. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer 2006;6:835-845.
10. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
12. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat 1998;52:239-259.
13. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-2356.
14. Ostrand-Rosenberg S, Sinha P, Danna EA, Miller S, Davis C, Dissanayake SK. Antagonists of tumor-specific immunity: Tumor-induced immune suppression and host genes that co-opt the anti-tumor immune response. Breast Dis 2004;20:127-135.
15. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266.
16. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
17. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67:5064-5066.
18. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92:1085-1091.
19. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6:3282-3289.
20. Yu JL, Rak JW. Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003;5:83-88.
21. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527.
22. Knowles H, Leek R, Harris AL. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Symp 2004;256:189-200; discussion 200-204, 259-269.
23. Varney ML, Olsen KJ, Mosley RL, Bucana CD, Talmadge JE, Singh RK. Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: A paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo 2002;16: 471-477.
24. Varney ML, Olsen KJ, Mosley RL, Singh RK. Paracrine regulation of vascular endothelial growth factor-a expression during macrophagemelanoma cell interaction: Role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res 2005;25:674-683.
25. Ravetch JV. Fc receptors. Curr Opin Immunol 1997;9:121-125.
26. Jayaram Y, Buckle AM, Hogg N. The Fc receptor. FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma. Clin Exp Immunol 1989;75:414-420.
27. Westwood NB, Copson ER, Page LA, Mire-Sluis AR, Brown KA, Pearson TC. Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythaemia. J Clin Pathol 1995;48:525-530.
28. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 1999;256:110-113.
29. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201.
30. Schaer CA, Vallelian F, Imhof A, Schoedon G, Schaer DJ. CD163-expressing monocytes constitute an endotoxin-sensitive Hb clearance compartment within the vascular system. J Leukoc Biol 2007; 82:106-110.
31. Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 2005;63:16-22.
32. n Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 2002;72:711-717.
33. Zarev PV, Davis BH. Comparative study of monocyte enumeration by flow cytometry: Improved detection by combining monocyterelated antibodies with anti-CD163. Lab Hematol 2004;10:24-31.
34. Goon PK, Boos CJ, Stonelake PS, Lip GY. Circulating endothelial cells in malignant disease. Future Oncol 2005;1:813-820.
35. Khan SS, Solomon MA, McCoy JP Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005;64B:1-8.
36. Davis BH. Improved diagnostic approaches to infection/sepsis detection. Expert Rev Mol Diagn 2005;5:193-207.
37. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97:77-89.
38. Fotino M, Merson EJ, Allen FH Jr. Micromethod for rapid separation of lymphocytes from peripheral blood. Ann Clin Lab Sci 1971;1:131-133.
39. Schlenke P, Kluter H, Muller-Steinhardt M, Hammers HJ, Borchert K, Bein G. Evaluation of a novel mononuclear cell isolation procedure for serological HLA typing. Clin Diagn Lab Immunol 1998;5:808-813.
40. Allan AL, Vantyghem SA, Tuck AB, Chambers AF, Chin-Yee IH, Keeney M. Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry A 2005; 65A:4-14.
41. Dawood S, Cristofanilli M. Integrating circulating tumor cell assays into the management of breast cancer. Curr Treat Options Oncol 2007;8:89-95.
42. Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci USA 1995;92:537-541.
43. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998;95:4589-4594.
44. Schiff DE, Rae J,Martin TR, Davis BH, Curnutte JT. Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 1997;90:3187-3194.
45. Allen E, Bakke AC, Purtzer MZ, Deodhar A. Neutrophil CD64 expression: Distinguishing acute inflammatory autoimmune disease from systemic infections. Ann Rheum Dis 2002;61:522-525.
46. Fjaertoft G, Hakansson LD, Pauksens K, Sisask G, Venge P. Neutrophil CD64 (FcgammaRI) expression is a specific marker of bacterial infection: A study on the kinetics and the impact of major surgery. Scand J Infect Dis 2007;39:525-535.
47. Matsui T, Ohsumi K, Ozawa N, Shimada K, Sumitomo S, Shimane K, Kawakami M, Nakayama H, Sugii S, Ozawa Y, Tohma S. CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. J Rheumatol 2006;33: 2416-2424.
48. Saxton JM, Claxton D, Winter E, Pockley AG. Peripheral blood leucocyte functional responses to acute eccentric exercise in humans are influenced by systemic stress, but not by exercise-induced muscle damage. Clin Sci (Lond) 2003;104:69-77.
49. Torsteinsdottir I, Arvidson NG, Hallgren R, Hakansson L. Monocyte activation in rheumatoid arthritis (RA): Increased integrin. Fc gamma and complement receptor expression and the effect of glucocorticoids. Clin Exp Immunol 1999;115:554-560.
50. Wolf Z, Orso E, Werner T, Klunemann HH, Schmitz G. Monocyte cholesterol homeostasis correlates with the presence of detergent resistant membrane microdomains. Cytometry A 2007;71A:486-494.
51. Viedma Contreras JA. Leucocyte activation markers in clinical practice. Clin Chem Lab Med 1999;37:607-622.
52. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-459.
53. Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. Thromb Haemost 2006;96:45-52.
54. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007;71A:105-113.
55. Elshal MF, Khan SS, Raghavachari N, Takahashi Y, Barb J, Bailey JJ, Munson PJ, Solomon MA, Danner RL, McCoy JP Jr. A unique population of effector memory lymphocytes identified by CD146 having a distinct immunophenotypic and genomic profile. BMC Immunol 2007;8:29.
56. Elshal MF, Khan SS, Takahashi Y, Solomon MA, McCoy JP Jr. CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood 2005;106:2923-2924.
57. Widemann A, Sabatier F, Arnaud L, Bonello L, Al-Massarani G, Paganelli F, Poncelet P, Dignat-George F. CD146-based immunomagnetic enrichment followed by multiparameter flow cytometry: A new approach to counting circulating endothelial cells. J Thromb Haemost 2008;6:869-876.
58. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004;15:139-145.
59. Furstenberger G, von Moos R, Senn HJ, Boneberg EM. Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. Br J Cancer 2005;93:793-798.
60. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.
61. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: Proposal of a definition and a consensus protocol. J Thromb Haemost 2006;4:671-677.
62. Bergeron M, Lustyik G, Phaneuf S, Ding T, Nicholson JK, Janossy G, Shapiro H, Barnett D, Mandy F. Stability of currently used cytometers facilitates the identification of pipetting errors and their volumetric operation: "time" can tell all. Cytometry B Clin Cytom 2003; 52B:37-39.